Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib combined with TACE or HAIC for hepatocellular carcinoma
ChiCTR2100054041Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Shandong Cancer Hospital. Primary endpoints: objective response rate, adverse events and 1 more. Started Oct 2021; status: recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100054041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054041.